TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A Being Patient report describes four leading theories of Alzheimer’s: amyloid buildup, tau tangles, inflammation and vascular damage. These ideas help guide research and treatment, but the causes of neuronal damage are not fully settled, and no one theory explains the disease on its own.
Researchers have not established a single cause of Alzheimer’s disease, but four leading theories focus on amyloid plaques, tau tangles, immune-system inflammation and damage to the brain’s blood vessels. A Being Patient report explains how each may contribute to the loss of neurons and why scientists continue to test how the processes interact.
Alzheimer’s is a progressive disease that damages and kills neurons, disrupting the connections through which brain cells communicate. The resulting damage can affect memory, language, judgment, behavior and, as the disease advances, physical coordination. Researchers are still working to determine what sets that damage in motion and how the different processes relate.
The amyloid hypothesis proposes that beta-amyloid fragments accumulate outside neurons, forming plaques that may interfere with cell signaling and contribute to further damage. A second theory focuses on tau tangles inside neurons: tau normally supports structures that help cells function, while abnormal tau can clump and disrupt those structures. The source report describes amyloid and tau as major lines of investigation, not a complete explanation of Alzheimer’s.
Two other theories examine inflammation and vascular damage. Inflammation involves the brain’s immune response, which may become harmful if it remains active or responds improperly. The vascular theory looks at injury to blood vessels and impaired blood flow, which could deprive brain tissue of oxygen and nutrients or hinder waste removal. The supplied source excerpt ends during its account of the tau theory, so it does not provide detailed evidence or named expert comments for these two theories.
How the Theories Shape Research
Theories of disease matter because they influence which biological processes researchers target in clinical trials and how they interpret possible treatments. The amyloid hypothesis has had a particularly large effect on drug development. The source reports that the FDA-approved antibodies lecanemab and donanemab modestly slowed cognitive decline in clinical trials among people in early stages of Alzheimer’s. They are not cures and carry risks, including brain swelling and bleeding, that require monitoring.
The mixed history of amyloid-focused treatments also illustrates why researchers continue to investigate other mechanisms. The source says Aduhelm (aducanumab) reduced plaques, but evidence of clinical benefit was unconvincing; its maker discontinued the drug in 2024. A treatment’s effect on a disease-related marker does not by itself establish that the marker is the sole cause or that changing it will meaningfully alter symptoms.
For patients and families, the distinction matters: a leading theory is not a settled explanation, and a treatment that affects one process may provide limited benefit without stopping the disease. Understanding how pathways may combine could help researchers identify who might benefit from particular treatments and what other targets need study.
Alzheimer's disease brain health supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From Plaques to Multiple Pathways
In 1906, German psychiatrist Alois Alzheimer described changes he observed in the brain of Auguste Deter, who had experienced worsening memory loss and other symptoms. The deposits and fiber bundles he reported are now known as amyloid plaques and tau tangles, hallmarks that remain central to Alzheimer’s research. Their presence, however, does not settle exactly how the disease begins or progresses.
The source characterizes amyloid as the dominant hypothesis for more than three decades. In this account, beta-amyloid can build up over many years before symptoms appear and may contribute to downstream damage, including tau changes. Amyloid is also used in diagnosis: the report says plaques can be identified with PET imaging and spinal-fluid testing, and that the FDA cleared a blood test to aid identification of amyloid pathology in May 2025.
The report estimates that 7.4 million Americans age 65 and older were living with Alzheimer’s dementia, citing the Alzheimer’s Association’s 2026 Facts and Figures report. That figure is an estimate for that age group, not a count of all people affected by Alzheimer’s in the United States.
““Both γ-secretase and β-secretase inhibitors, which strongly inhibit amyloid-beta production, worsen cognitive and clinical performance in early and late stages of Alzheimer’s disease.””
— Bruno Imbimbo, a researcher at Chiesi Farmaceutici, as quoted by Being Patient
memory support supplements for seniors
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What Scientists Have Yet to Resolve
No single theory has been shown to explain all Alzheimer’s disease, and the supplied report presents several competing or potentially connected mechanisms. It remains unclear how much each contributes, which processes start the chain of damage, and whether one pathway drives the others or several develop together.
The source also notes disagreement about amyloid’s role. Some researchers have proposed that beta-amyloid could have a protective function, while Imbimbo points to inhibitor trials that he says worsened clinical performance. The supplied material does not provide study details that would allow readers to assess that claim independently. Evidence that a treatment changes plaques, meanwhile, is distinct from evidence that it improves a person’s daily functioning.
Because the source excerpt is incomplete, it does not give comparable detail on the evidence for inflammation or vascular damage, or explain how those theories may overlap with amyloid and tau. The timing and order of these processes also remain unsettled in the material provided.
As an affiliate, we earn on qualifying purchases.
Research Beyond Amyloid Targets
Researchers continue to test treatments aimed at amyloid and other disease processes, while studying how biomarkers can identify Alzheimer’s-related changes. For people receiving approved anti-amyloid antibodies, the source reports that regular monitoring is needed because of the risk of brain swelling and bleeding. Those drugs are intended for people in early stages, according to the report, and are not cures.
Further clinical results will help clarify how much these treatments affect symptoms and which patients are most likely to benefit. Research into tau, inflammation and vascular injury may also show whether combining targets or treating different processes at different stages offers a stronger approach. The source does not specify upcoming trial dates or particular planned milestones, so the timing of new findings is unclear.
As an affiliate, we earn on qualifying purchases.
Key Questions
What are the four leading theories about Alzheimer’s?
The report discusses amyloid buildup, tau tangles, inflammation and vascular damage. They describe possible contributors to neuronal injury, rather than four proven, separate causes.
Is amyloid proven to be the sole cause of Alzheimer’s?
No. Amyloid has guided much Alzheimer’s research, but the source describes continuing scientific disagreement and says researchers are still working out why neurons die. It does not establish amyloid as the sole cause.
Do current amyloid treatments cure Alzheimer’s?
No. The report says lecanemab and donanemab modestly slowed cognitive decline in clinical trials among people in early stages. It describes them as not cures and notes risks that require monitoring.
How do researchers detect amyloid?
According to the report, amyloid plaques can be assessed with PET scans and spinal-fluid testing. It also says the FDA cleared a blood test in May 2025 to aid identification of amyloid pathology linked to Alzheimer’s.
What remains uncertain about Alzheimer’s causes?
Researchers have not settled which processes start the disease, how they interact or how much each contributes. The supplied report excerpt also offers limited detail on the evidence for inflammation and vascular damage.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
